Vertex Pharmaceuticals Valuation

VRTX -- USA Stock  

USD 177.55  2.61  1.49%

Vertex Pharmaceuticals has current Real Value of $192.05 per share. The regular price of the company is $177.55. At this time the company appears to be undervalued. This module measures value of Vertex Pharmaceuticals from inspecting the company fundamentals such as Shares Outstanding of 257.04M, Return On Equity of 56.25% and Operating Margin of 29.00% as well as reviewing its technical indicators and Probability Of Bankruptcy. In general, we recommend to buy undervalued stocks and to dispose of overvalued stocks since at some point securities prices and their ongoing real values will draw towards each other.
Undervalued
September 16, 2019
177.55
Market Value
159.80
Downside
192.05
Real Value
197.42
Upside
Vertex Pharmaceuticals is very steady asset. Calculation of real value of Vertex Pharmaceuticals is based on 3 months time horizon. Increasing Vertex Pharmaceuticals time horizon generally increases accuracy of value calculation and significantly improves predictive power of the methodology used.
Investments

Valuation Drivers Correlation

Click cells to compare fundamentals   View All Correlations
Vertex Pharmaceuticals Incorpor Valuation Data Drivers
Net Income Per Employee    Enterprise Value    Market Capitalization    

Vertex Pharmaceuticals Market Cap

Vertex Pharmaceuticals Incorpor is rated below average in market capitalization category among related companies. Market capitalization of Biotechnology industry is at this time estimated at about 192.4 Billion. Vertex Pharmaceuticals totals roughly 45.64 Billion in market capitalization claiming about 24% of stocks in Biotechnology industry.
Capitalization  Valuation  Revenue  Workforce  Total debt
Horizon     30 Days    Login   to change
Vertex Pharmaceuticals Incorpor is rated below average in price to sales category among related companies. It is rated below average in beta category among related companies totaling about  0.08  of Beta per Price to Sales. The ratio of Price to Sales to Beta for Vertex Pharmaceuticals Incorpor is roughly  12.58 

Valuation Basics

Vertex Pharmaceuticals Enterprise Value Fundamentals

Quick Ratio3.51
Earnings Quarterly Growth29.00%
Revenue Growth25.10%
Enterprise Value To Ebitda41.60
Earnings Growth28.50%
Enterprise Value To Revenue12.06

Valuation Indicators

Vertex Pharmaceuticals Valuation Fundamental Ratios

Also please take a look at World Market Map. Please also try Portfolio Reporting module to create custom reports across your portfolios and generate quick suggestion pitch.
Search macroaxis.com